Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Extrawell Pharmaceutical HoldingsHKSE:00858 Median PS Value is HK$0.08 as of Sep. 20, 2026. The stock has 5 warning signs investors should review. Among 560 Drug Manufacturers companies, Extrawell Pharmaceutical Holdings ranks worse than 63.93% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Extrawell Pharmaceutical Holdings's Median PS Value or its related term are showing as below:
HKSE:00858'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.25 Med: 0.64 Max: 1.09
Current: 1.05
During the past 13 years, the highest Price to Median PS Value of Extrawell Pharmaceutical Holdings was 1.09. The lowest was 0.25. And the median was 0.64.
HKSE:00858's Price-to-Median-PS-Value is ranked worse than 63.93% of 560
companies
in the Drug Manufacturers industry
Industry Median: 0.86
vs HKSE:00858: 1.05
Extrawell Pharmaceutical Holdings (HKSE:00858) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Extrawell Pharmaceutical Holdings's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.084
/
0.08
=
1.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Extrawell Pharmaceutical Holdings Median PS Value Related Terms
Extrawell Pharmaceutical Holdings Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Extrawell Pharmaceutical Holdings Median PS Value Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Extrawell Pharmaceutical Holdings Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Extrawell Pharmaceutical Holdings's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 3.8095.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Extrawell Pharmaceutical Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was HK$0.021.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Extrawell Pharmaceutical Holdings (HKSE:00858) has a Median PS Value of HK$0.08 as of Sep. 20, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Extrawell Pharmaceutical Holdings and its competitors. According to the industry distribution chart, Extrawell Pharmaceutical Holdings ranks #358 out of 560 companies in the Drug Manufacturers industry, placing it in the top 63.9%.
Is Extrawell Pharmaceutical Holdings' Median PS Value too high?
Extrawell Pharmaceutical Holdings' current Median PS Value is HK$0.08. Based on the distribution chart, Extrawell Pharmaceutical Holdings ranks #358 out of 560 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Extrawell Pharmaceutical Holdings' Median PS Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Extrawell Pharmaceutical Holdings ranks #358 out of 560 companies for Median PS Value. This places Extrawell Pharmaceutical Holdings in the lower half of its industry. The industry median Median PS Value is 0.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.86, based on 560 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Extrawell Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Extrawell Pharmaceutical Holdings's current Median PS Value is HK$0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extrawell Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Extrawell Pharmaceutical Holdings (HKSE:00858) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.05, compared to a current price of HK$0.08 — trading 68% above its estimated fair value. The current Median PS Value is HK$0.08. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Extrawell Pharmaceutical Holdings (HKSE:00858), the current Median PS Value is HK$0.08 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing, Trading, and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. Geographically, it derives a majority of its revenue from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00858 has been successfully added to your 
